EMA Recommends Extension of Indications for Pembrolizumab
New indication concerns mono or combination with chemotherapy in the first-line treatment of metastatic or unresectable recurrent HNSCC
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
Social Outcomes after Adolescent and Young Adult Cancer
A programme of research into social outcomes after AYA cancer and its treatment
The Nobel Prize in Physiology or Medicine 2019
Awarded discoveries paved the way for promising new strategies to fight anaemia, cancer and many other diseases
Four-Week Limit for Use of High-Strength Oestradiol Creams
Systemic exposure to oestradiol could be associated with endometrial hyperplasia/carcinoma, breast and ovarian cancer and thromboembolic events
How To Ensure That Novel Analytic Methods Are Fit for Decision-Making
Making novel analytical methods acceptable for regulators and other decision makers requires their testing and validation prospectively...
FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma
Evidence for efficacy is based on the results from CASSIOPEIA trial
EMA Recommends Extension of Indications for Taxotere and Docetaxel Zentiva
New indication concerns the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with androgen-deprivation therapy, with or without prednisone or prednisolone
Adding Atezolizumab to Front-Line Platinum-Based Chemotherapy Improves Progression-Free Survival in mUC
Atezolizumab administered with chemotherapy was well-tolerated in patients with metastatic urothelial cancer
Olaparib Outperforms Enzalutamide or Abiraterone Acetate in Men with mCRPC and HRR Alterations
A clinically meaningful benefit in radiographic progression-free survival was provided by olaparib in men with metastatic castration-resistant prostate cancer who had progressed on prior treatment with new hormonal anticancer treatments
Ivosidenib Provides Prolonged Progression-Free Survival in Patients with Cholangiocarcinoma and IDH1 Mutation
Ivosidenib may be a new treatment option for rare cholangiocarcinoma in patients with an isocitrate dehydrogenase 1 mutation
Efficacy Differences Are Observed According to Patients’ Sex with Immunotherapy in Advanced Solid Tumours
Survival benefit following immune blockade also differs in men and women when the agent is administered as monotherapy or in combination with chemotherapy
First Report of Head and Neck Squamous Cell Carcinoma Treatment Individualised by Geriatric Assessment
Fit and unfit elderly patients derive different benefit from systemic treatment for HNSCC